Pharmaceutical Technology Editors

Jones Packaging introduces a new solid dose vial line in its Toronto facility.

According to the National Bioscience Report, the US bioscience industry is on course for continued growth.

Abbott will acquire a controlling interest in the Russian pharmaceutical manufacturer Veropharm.

FDA approved Cubist's treatment for skin infections including MRSA.

Shire reports that AbbVie offer undervalued company.

Dr. Reddy's recalls blood pressure drug due to failed dissolution tests.

FDA cites cGMP violations for API manufacturing at a facility in Tianjin, China.

New services manage clinical or drug manufacturing data in the Verizon cloud or from data centers.

Arecor and the Center for Process Innovation (CPI) Biologics are working on a project to enhance the compatibility of biologics with their containers.

FDA inspection found cGMP violations in the Bangalore, India API manufacturing facility.

Hospira announces a voluntary nationwide recall due to particulates from a glass defect.

The National Institutes of Health and the National Science Foundation set up biomedical innovation and business program.

EDQM details the agency?s accomplishments in 2013.

FDA issues guidance on the use of social media in regards to prescription drugs.

ISPE Metrics Pilot Program is designed to demonstrate the feasibility and value of standard quality metrics.

Funding boosts life-sciences manufacturing in West Michigan.

FDA provides advice to supply-chain stakeholders on how to identify suspect drug products and how to notify the agency of those products.

Novartis facility becomes the first US site licensed by the FDA to produce cell-culture influenza vaccines.

Catalent and AAPS announce the five winners of its annual academic competition.

EMA has published a new guidance template for the qualified person’s declaration concerning GMP compliance of API manufacture. The QP declaration template provides the basis for demonstrating compliance of the API manufacture with GMP requirements and ensures that the manufacturer has sufficient knowledge on the supply chain.

The fabrication facility will supply modular construction to the US life-science market.

The new mAb manufacturing facility in Switzerland will supply material for clinical development.

Draft guidance from FDA includes information essential for the completion of ANDA applications.

A new report from GlobalData states that biosimilars will overtake the market share after 2019.

USP and USAID give prequalification status to Capreomycin, an anti-tuberculosis injectable.

Xcelience opens a clinical packaging and distribution facility in Birmingham, UK.

APIC provides guidance on cleaning validation in API plants and how to implement GDP for APIs.

Despite GMP deficiencies, EMA reinstates GMP certificate for Ranbaxy's Toansa facility, citing no threat to public health.

Malvern Instruments will acquire the MicroCal business from GE Healthcare Life Sciences.

Genia's DNA-sequencing platform will strengthen Roche's pipeline.